专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110212439A1 HLA ALLELES ASSOCIATED WITH ADVERSE DRUG REACTIONS AND METHODS FOR DETECTING SUCH 有权
标题翻译：与不良药物反应相关的HLA ALLELES及其检测方法
公开(公告)号：US20110212439A1
公开(公告)日：2011-09-01
申请号：US13100665
申请日：2011-05-04
申请人： YUAN-TSONG CHEN , SHUEN-IU HUNG , CHIH-LUNG SHEN , CHI-FENG CHANG , HSIN-YU LIN , WEI-HSUAN CHEN
发明人： YUAN-TSONG CHEN , SHUEN-IU HUNG , CHIH-LUNG SHEN , CHI-FENG CHANG , HSIN-YU LIN , WEI-HSUAN CHEN
IPC分类号： C12Q1/68 , G01N33/50
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/136 , C12Q2600/142 , C12Q2600/156 , C12Q2600/16 , C12Q2600/172 , Y10T436/143333
摘要： This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).
摘要翻译：本发明涉及确定某些HLA等位基因如HLA-B * 1502或HLA-B * 5801的存在的方法和用于实施该方法的试剂盒。还公开了一种基于遗传标记（例如HLA-B）的存在或不存在来评估患者是否处于发展不良药物反应（例如，史蒂文斯 - 约翰逊综合征，中毒性表皮坏死松解症或超敏反应综合征）的风险中的方法 * 1502，HLA-B * 5801或HLA-B * 4601）。

2. 发明申请

US20080145846A1 HLA ALLELES ASSOCIATED WITH ADVERSE DRUG REACTIONS AND METHODS FOR DETECTING SUCH 有权
标题翻译：与不良药物反应相关的HLA ALLELES及其检测方法
公开(公告)号：US20080145846A1
公开(公告)日：2008-06-19
申请号：US11747674
申请日：2007-05-11
申请人： Yuan-Tsong Chen , Shuen-lu Hung , Chih-Lung Shen , Chi-Feng Chang , Hsin-Yu Lin , Wei-Hsuan Chen
发明人： Yuan-Tsong Chen , Shuen-lu Hung , Chih-Lung Shen , Chi-Feng Chang , Hsin-Yu Lin , Wei-Hsuan Chen
IPC分类号： C12Q1/68 , C12Q1/02
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/136 , C12Q2600/142 , C12Q2600/156 , C12Q2600/16 , C12Q2600/172 , Y10T436/143333
摘要： This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).
摘要翻译：本发明涉及确定某些HLA等位基因如HLA-B * 1502或HLA-B * 5801的存在的方法以及用于实施该方法的试剂盒。还公开了一种基于遗传标记（例如HLA-B）的存在或不存在来评估患者是否处于发展不良药物反应（例如，史蒂文斯 - 约翰逊综合征，中毒性表皮坏死松解症或超敏反应综合征）的风险中的方法 * 1502，HLA-B * 5801或HLA-B * 4601）。

3. 发明申请

US20070298426A1 WARFARIN DOSAGE PREDICTION 审中-公开
标题翻译： WARFARIN剂量预测
公开(公告)号：US20070298426A1
公开(公告)日：2007-12-27
申请号：US11757860
申请日：2007-06-04
申请人： Yuan-Tsong Chen , Chih-Lung Shen , Chi-Feng Chang , Ming Ta Lee , Jen-Chi Hsu , Liang-Suei Lu , Ming-Shen Wen
发明人： Yuan-Tsong Chen , Chih-Lung Shen , Chi-Feng Chang , Ming Ta Lee , Jen-Chi Hsu , Liang-Suei Lu , Ming-Shen Wen
IPC分类号： C12Q1/68 , A61K31/366
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： This invention relates to predicting a patient's warfarin dose based on the nucleotide at position −1639 of the VKORC1 gene and the genotype of the CYP2C9 gene in that patient. The warfarin dose so predicted can be further adjusted according to the patient's non-genetic factors, e.g., age, body surface area, medical conditions, and use or non-use of certain drugs.
摘要翻译：本发明涉及基于VKORC1基因位置-1639处的核苷酸和该患者中CYP2C9基因的基因型来预测患者的华法林剂量。如此预测的华法林剂量可以根据患者的非遗传因素进一步调整，例如年龄，体表面积，医疗条件以及某些药物的使用或不使用。

4. 发明授权

US09409381B2 Reusable multilayer and multifunctional floor underlay 有权
标题翻译：可重复使用的多层和多功能地板底层
公开(公告)号：US09409381B2
公开(公告)日：2016-08-09
申请号：US14830811
申请日：2015-08-20
申请人： Chi-Feng Chang
发明人： Ta-Wei Chang
IPC分类号： E04F15/16 , B32B29/00 , B32B5/02 , B32B5/16 , B32B5/24 , B32B7/06 , B32B7/02 , E04F15/02 , E04F15/20
CPC分类号： B32B29/002 , B32B5/022 , B32B5/16 , B32B5/18 , B32B5/245 , B32B5/26 , B32B5/30 , B32B7/02 , B32B7/06 , B32B7/12 , B32B9/02 , B32B9/047 , B32B21/10 , B32B25/10 , B32B27/12 , B32B27/304 , B32B29/02 , B32B2255/04 , B32B2255/102 , B32B2255/26 , B32B2260/025 , B32B2262/065 , B32B2262/067 , B32B2264/0207 , B32B2264/0292 , B32B2264/065 , B32B2264/067 , B32B2264/12 , B32B2266/0207 , B32B2266/0278 , B32B2272/00 , B32B2307/102 , B32B2307/3065 , B32B2307/56 , B32B2307/5825 , B32B2307/7246 , B32B2405/00 , B32B2419/04 , B32B2471/00 , E04F15/02155 , E04F15/166 , E04F15/203 , Y10T428/14 , Y10T428/28 , Y10T428/2848
摘要： The present invention relates to a floor underlay, which is reusable and has multilayer and multifunctional characteristics. The floor underlay is used for joining the floor and floor decoration sheets. The structure of the floor underlay comprises adhesive layers, support layers, waterproof layers, and a multiple-media intermediate layer. The multiple-media intermediate layer is formed by mixing a plurality of medium particles. The medium particles are formed by elastic materials, such as rubber, rubber foam, polyurethane, or polyurethane foam. Thereby, the floor including the floor underlay will have the vibration absorption, sound absorption, flame resistive, and fall prevention functions.
摘要翻译：本发明涉及一种可重复使用并具有多层和多功能特性的地板底垫。地板底层用于连接地板和地板装饰板。地板底层的结构包括粘合剂层，支撑层，防水层和多介质中间层。通过混合多个介质颗粒形成多介质中间层。中等颗粒由橡胶，橡胶泡沫，聚氨酯或聚氨酯泡沫等弹性材料形成。因此，包括地板底层的地板将具有振动吸收，吸音，防火和防坠落功能。

5. 发明申请

US20160053497A1 REUSABLE MULTILAYER AND MULTIFUNCTIONAL FLOOR UNDERLAY 有权
标题翻译：可重复使用的多层和多功能楼层
公开(公告)号：US20160053497A1
公开(公告)日：2016-02-25
申请号：US14830811
申请日：2015-08-20
申请人： CHI-FENG CHANG
发明人： TA-WEI CHANG
IPC分类号： E04F15/16 , B32B5/24 , B32B29/00 , B32B7/02 , B32B5/16 , B32B5/02 , B32B7/06
CPC分类号： B32B29/002 , B32B5/022 , B32B5/16 , B32B5/18 , B32B5/245 , B32B5/26 , B32B5/30 , B32B7/02 , B32B7/06 , B32B7/12 , B32B9/02 , B32B9/047 , B32B21/10 , B32B25/10 , B32B27/12 , B32B27/304 , B32B29/02 , B32B2255/04 , B32B2255/102 , B32B2255/26 , B32B2260/025 , B32B2262/065 , B32B2262/067 , B32B2264/0207 , B32B2264/0292 , B32B2264/065 , B32B2264/067 , B32B2264/12 , B32B2266/0207 , B32B2266/0278 , B32B2272/00 , B32B2307/102 , B32B2307/3065 , B32B2307/56 , B32B2307/5825 , B32B2307/7246 , B32B2405/00 , B32B2419/04 , B32B2471/00 , E04F15/02155 , E04F15/166 , E04F15/203 , Y10T428/14 , Y10T428/28 , Y10T428/2848
摘要： The present invention relates to a floor underlay, which is reusable and has multilayer and multifunctional characteristics. The floor underlay is used for joining the floor and floor decoration sheets. The structure of the floor underlay comprises adhesive layers, support layers, waterproof layers, and a multiple-media intermediate layer. The multiple-media intermediate layer is formed by mixing a plurality of medium particles. The medium particles are formed by elastic materials, such as rubber, rubber foam, polyurethane, or polyurethane foam. Thereby, the floor including the floor underlay will have the vibration absorption, sound absorption, flame resistive, and fall prevention functions.
摘要翻译：本发明涉及一种可重复使用并具有多层和多功能特性的地板底垫。地板底层用于连接地板和地板装饰板。地板底层的结构包括粘合剂层，支撑层，防水层和多介质中间层。通过混合多个介质颗粒形成多介质中间层。中等颗粒由橡胶，橡胶泡沫，聚氨酯或聚氨酯泡沫等弹性材料形成。因此，包括地板底层的地板将具有振动吸收，吸音，防火和防坠落功能。

6. 发明授权

US08142999B2 HLA alleles associated with adverse drug reactions and methods for detecting such 有权
标题翻译：与药物不良反应有关的HLA等位基因及其检测方法
公开(公告)号：US08142999B2
公开(公告)日：2012-03-27
申请号：US13100665
申请日：2011-05-04
申请人： Yuan-Tsong Chen , Shuen-Iu Hung , Chih-Lung Shen , Chi-Feng Chang , Hsin-Yu Lin , Wei-Hsuan Chen
发明人： Yuan-Tsong Chen , Shuen-Iu Hung , Chih-Lung Shen , Chi-Feng Chang , Hsin-Yu Lin , Wei-Hsuan Chen
IPC分类号： C12Q1/68 , C12P19/34 , C12M1/34
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/136 , C12Q2600/142 , C12Q2600/156 , C12Q2600/16 , C12Q2600/172 , Y10T436/143333
摘要： This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).
摘要翻译：本发明涉及确定某些HLA等位基因如HLA-B * 1502或HLA-B * 5801的存在的方法以及用于实施该方法的试剂盒。还公开了一种基于遗传标记（例如HLA-B）的存在或不存在来评估患者是否处于发展不良药物反应（例如，史蒂文斯 - 约翰逊综合征，中毒性表皮坏死松解症或超敏反应综合征）的风险中的方法 * 1502，HLA-B * 5801或HLA-B * 4601）。

7. 发明申请

US20150337386A1 TEST COMPOSITION FOR SCREENING CANCERS 审中-公开
标题翻译：用于筛选癌症的试验组合物
公开(公告)号：US20150337386A1
公开(公告)日：2015-11-26
申请号：US14423416
申请日：2012-08-28
申请人： Chi-Feng CHANG , Huei-Jen WANG , Yu-Ligh LIOU
发明人： Chi-Feng CHANG , Huei-Jen WANG , Yu-Ligh LIOU
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/154 , C12Q2600/166
摘要： Provided in the present invention are a molecule for biomarking cancers and a test composition for screening cancers and a detection method thereof comprising designing a number of oligonucleotide primers or probes by analyzing specimens for methylated regions of targeted genes PAX1, ZNF582, SOX1 and NKX6-1 in physical examination, and then using the oligonucleotide probes to detect whether methylation exists in the target genes, and further judge the likelihood of the occurrence of cancer. The detection methods for methylation status include methylation-specific PCR, (MSP), quantitative methylation-specific PCR (QMSP), bisulfate sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), pyrosequencing, and enzyme-linked immunosorbent assay (ELISA).
摘要翻译：本发明提供了一种用于生物标记癌症的分子和用于筛选癌症的测试组合物及其检测方法，其包括通过分析靶向基因PAX1，ZNF582，SOX1和NKX6-1的甲基化区域的标本来设计多个寡核苷酸引物或探针在体检中，然后使用寡核苷酸探针检测靶基因中是否存在甲基化，进一步判断癌症发生的可能性。甲基化状态的检测方法包括甲基化特异性PCR（MSP），定量甲基化特异性PCR（QMSP），硫酸氢盐测序（BS），微阵列，质谱仪，变性高效液相色谱（DHPLC），焦磷酸测序和酶连接的免疫吸附测定（ELISA）。

8. 发明授权

US07943309B2 HLA alleles associated with adverse drug reactions and methods for detecting such 有权
标题翻译：与药物不良反应有关的HLA等位基因及其检测方法
公开(公告)号：US07943309B2
公开(公告)日：2011-05-17
申请号：US11747674
申请日：2007-05-11
申请人： Yuan-Tsong Chen , Shuen-Iu Hung , Chih-Lung Shen , Chi-Feng Chang , Hsin-Yu Lin , Wei-Hsuan Chen
发明人： Yuan-Tsong Chen , Shuen-Iu Hung , Chih-Lung Shen , Chi-Feng Chang , Hsin-Yu Lin , Wei-Hsuan Chen
IPC分类号： C12Q1/68 , C12P19/34 , C12M1/34
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/136 , C12Q2600/142 , C12Q2600/156 , C12Q2600/16 , C12Q2600/172 , Y10T436/143333
摘要： This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).
摘要翻译：本发明涉及确定某些HLA等位基因如HLA-B * 1502或HLA-B * 5801的存在的方法和用于实施该方法的试剂盒。还公开了一种基于遗传标记（例如HLA-B）的存在或不存在来评估患者是否处于发展不良药物反应（例如，史蒂文斯 - 约翰逊综合征，中毒性表皮坏死松解症或超敏反应综合征）的风险中的方法 * 1502，HLA-B * 5801或HLA-B * 4601）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式